• Thierry Gustot, Javier Fernandez, Elisabet Garcia, Filippo Morando, Paolo Caraceni, Carlo Alessandria, Wim Laleman, Jonel Trebicka, Laure Elkrief, Corinna Hopf, Pablo Solís-Munoz, Faouzi Saliba, Stefan Zeuzem, Augustin Albillos, Daniel Benten, José Luis Montero-Alvarez, Maria Teresa Chivas, Mar Concepción, Juan Córdoba, Aiden McCormick, Rudolf Stauber, Wolfgang Vogel, Andrea de Gottardi, Tania M Welzel, Marco Domenicali, Alessandro Risso, Julia Wendon, Carme Deulofeu, Paolo Angeli, François Durand, Marco Pavesi, Alexander Gerbes, Rajiv Jalan, Richard Moreau, Pere Ginés, Mauro Bernardi, Vicente Arroyo, and CANONIC Study Investigators of the EASL-CLIF Consortium.
• Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
• Hepatology. 2015 Jul 1;62(1):243-52.

UnlabelledAcute-on-chronic liver failure (ACLF) is characterized by acute decompensation (AD) of cirrhosis, organ failure(s), and high 28-day mortality. We investigated whether assessments of patients at specific time points predicted their need for liver transplantation (LT) or the potential futility of their care. We assessed clinical courses of 388 patients who had ACLF at enrollment, from February through September 2011, or during early (28-day) follow-up of the prospective multicenter European Chronic Liver Failure (CLIF) ACLF in Cirrhosis study. We assessed ACLF grades at different time points to define disease resolution, improvement, worsening, or steady or fluctuating course. ACLF resolved or improved in 49.2%, had a steady or fluctuating course in 30.4%, and worsened in 20.4%. The 28-day transplant-free mortality was low-to-moderate (6%-18%) in patients with nonsevere early course (final no ACLF or ACLF-1) and high-to-very high (42%-92%) in those with severe early course (final ACLF-2 or -3) independently of initial grades. Independent predictors of course severity were CLIF Consortium ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin ≥12 mg/dL) at ACLF diagnosis. Eighty-one percent had their final ACLF grade at 1 week, resulting in accurate prediction of short- (28-day) and mid-term (90-day) mortality by ACLF grade at 3-7 days. Among patients that underwent early LT, 75% survived for at least 1 year. Among patients with ≥4 organ failures, or CLIF-C ACLFs >64 at days 3-7 days, and did not undergo LT, mortality was 100% by 28 days.ConclusionsAssessment of ACLF patients at 3-7 days of the syndrome provides a tool to define the emergency of LT and a rational basis for intensive care discontinuation owing to futility.© 2015 by the American Association for the Study of Liver Diseases.

12 keywords...

hide…